| Literature DB >> 28466410 |
Tetsuo Horimatsu1, Kenichi Fujii2, Masashi Fukunaga1, Kojiro Miki1, Machiko Nishimura1, Yoshiro Naito1, Masahiko Shibuya1, Takahiro Imanaka1, Kenji Kawai1, Hiroto Tamaru1, Akinori Sumiyoshi1, Ten Saita1, Tohru Masuyama1, Masaharu Ishihara1.
Abstract
In addition to plaque rupture (PR), calcified nodule (CN) may also have the potential to develop into arterial thrombus in the peripheral arteries. This study evaluated the distribution of plaque ruptures and calcified nodules in the peripheral arteries and their impact on the outcome of endovascular therapy (EVT). Consecutive 159 patients who underwent EVT with intravascular ultrasound guidance were enrolled. The position of CNs and PRs were assigned to any of common iliac artery, external iliac artery, common femoral artery, and superficial femoral artery. Forty-six (29%) patients had calcified nodule and twenty-eight (18%) patients had plaque rupture somewhere in the lower limb arteries. Although calcified nodules were evenly distributed throughout the length of the arteries plaque ruptures were predominantly located in the proximal segment of the iliofemoral arteries. Stent expansion ratio was significantly smaller in the target arteries with calcified nodules than in those with plaque rupture. Multivariate logistic regression analysis identified hemodialysis as an independent clinical predictor of calcified nodule (odds ratio 8.15, 95% confidence interval 1.73-38.3; P = 0.008). CN definitely affects incomplete stent deployment in the peripheral artery contributing to adverse events, on the other hand, PR has more acceptable outcomes after stent implantation. In the clinical setting, it is important that we realize the features of peripheral artery disease and its patient characteristics which having CNs and PRs to make a strategy for revascularization.Entities:
Keywords: Calcified nodule; Peripheral artery disease; Plaque rupture
Mesh:
Year: 2017 PMID: 28466410 DOI: 10.1007/s00380-017-0984-5
Source DB: PubMed Journal: Heart Vessels ISSN: 0910-8327 Impact factor: 2.037